scholarly journals Prospective evaluation of clinical outcomes in all-comer high-risk patients with aortic valve stenosis undergoing medical treatment, transcatheter or surgical aortic valve implantation following heart team assessment

2013 ◽  
Vol 17 (3) ◽  
pp. 492-500 ◽  
Author(s):  
Christophe Dubois ◽  
Mark Coosemans ◽  
Filip Rega ◽  
Gert Poortmans ◽  
Ann Belmans ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Medical Treatment ◽  
Clinical Outcomes ◽  
Heart Team ◽  
Prospective Evaluation ◽  
Team Assessment ◽  
Risk Patients ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis – Overcoming the Challenges

2011 ◽  
Vol 6 (2) ◽  
pp. 165 ◽  
Author(s):  
Thomas Walther ◽  
Helge Möllmann ◽  
Johannes Blumenstein ◽  
Jörg Kempfert ◽  
◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Aortic Stenosis ◽  
Transcatheter Aortic Valve Implantation ◽  
Heart Team ◽  
High Risk Patients ◽  
Transcatheter Aortic Valve ◽  
Risk Patients ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Transcatheter aortic valve implantation (TAVI) has evolved as one of the most important innovations in cardiovascular medicine during the past five years. By means of transfemoral (TF) and transapical (TA) AVI elderly and high-risk patients with symptomatic aortic stenosis (AS) are being routinely treated using a minimally invasive approach. Some challenges have to be overcome to obtain perfect results: patient screening and eventual selection is important, conduct of the procedures by an experienced and interdisciplinary heart team is ideal and intense post-operative therapy is required for the patients. Currently available devices, the Corevalve™ (CV, Medtronic Inc.) and SAPIEN™ (ES, Edwards Inc.) prostheses, which are Conformité Européenne (CE) Mark approved for TF (CV and ES) and TA (ES) implantations, are first-generation prostheses. Future developments will focus on reduction of potential paravalvular leakage as well as improved features during valve implantation, most importantly repositioning and retrievability. TAVI has already gained an important position for the treatment of elderly high-risk patients with AS.

scholarly journals Trans-catheter Aortic Valve Implantation Guidelines – Does the Latest Evidence Change our Views?

2011 ◽  
Vol 9 (1) ◽  
pp. 26
Author(s):  
Hannah ZR McConkey ◽  
Bernard Prendergast ◽  
◽  
Keyword(s):  
Surgical Treatment ◽  
High Risk ◽  
Aortic Valve ◽  
Medical Treatment ◽  
Functional Status ◽  
Patient Selection ◽  
High Risk Patients ◽  
Risk Patients ◽  
Aortic Valve Implantation ◽  
Valve Implantation

From the wealth of recent registries and trials scrutinising its performance, trans-catheter aortic valve implantation (TAVI) emerges as a viable and rapidly established option, both when compared to medical treatment in inoperable patients and when compared to conventional surgical treatment in high-risk patients. Results consistently demonstrate improvement in functional status and outcome; however, appropriate patient selection remains crucial as high-risk cohorts become apparent.

Registry of Transcatheter Aortic-Valve Implantation in High-Risk Patients

2012 ◽  
Vol 366 (18) ◽  
pp. 1705-1715 ◽  
Author(s):  
Martine Gilard ◽  
Hélène Eltchaninoff ◽  
Bernard Iung ◽  
Patrick Donzeau-Gouge ◽  
Karine Chevreul ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
High Risk Patients ◽  
Transcatheter Aortic Valve ◽  
Risk Patients ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Analysis of Survival in 300 High-Risk Patients up to 2.5 Years After Transapical Aortic Valve Implantation

2011 ◽  
Vol 92 (4) ◽  
pp. 1315-1323 ◽  
Author(s):  
Axel Unbehaun ◽  
Miralem Pasic ◽  
Thorsten Drews ◽  
Stephan Dreysse ◽  
Marian Kukucka ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
High Risk Patients ◽  
Risk Patients ◽  
Aortic Valve Implantation ◽  
Valve Implantation
Sign in / Sign up

Export Citation Format

Share Document